Assessing the Ability of the T-SPOT®.TB Test (IQ) (IQ)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03973970|
Recruitment Status : Not yet recruiting
First Posted : June 4, 2019
Last Update Posted : August 29, 2019
|Condition or disease|
This study will enroll up to 202 subjects (assumes 15 % exclusion/drop-out rate). The target number of subjects is 75 active TB (recruited from subjects presenting at TB clinics) and 100 active TB excluded (recruited from subjects in the community).
All subjects enrolled in this study will be men or women, aged 18 years or older.
Duration: 1 year
|Study Type :||Observational|
|Estimated Enrollment :||202 participants|
|Official Title:||Assessing the Ability of the T-SPOT®.TB Test to Identify Those at Risk of Active Mycobacterium Tuberculosis Infection Using the Normalized Tuberculosis (TB) Specific Lymphocyte Response.|
|Estimated Study Start Date :||September 30, 2019|
|Estimated Primary Completion Date :||September 30, 2020|
|Estimated Study Completion Date :||September 30, 2020|
Test Arm 1- T-SPOT.TB assay
Test Arm 1: T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert.
Test Arm 2-QuantiFERON-TB Gold Plus assay
Test Arm 2: QuantiFERON-TB Gold Plus For each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert.
- T Spot [ Time Frame: 1 year ]The primary objective of this study is to demonstrate performance of the normalized Tuberculosis (TB) specific lymphocyte response (NTBSLR) in identifying patients with active Tuberculosis (TB) disease.
- T Spot [ Time Frame: 1 year ]The secondary exploratory objective is to demonstrate that active Tuberculosis (TB) cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based Interferon-Gamma Release Assay (IGRA).
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03973970
|Contact: Maya Peltzfirstname.lastname@example.org|
|United States, Texas|
|University of Texas Health||Not yet recruiting|
|Brownsville, Texas, United States, 78520|
|Contact: Marielena (Anette) Benavidez Marielena.A.Benavidez@uth.tmc.edu|
|Principal Investigator: Blanca Restrepo, MD|
|Principal Investigator:||Blanca Restrepo, MD||UTHealth Houston, School of Public Health|